Cellebrite DI Ltd. (NASDAQ:CLBT) Stock Has Consensus Price Target of $14.75

Key Points

• Analyst sentiment is moderately positive: Four of five covering firms rate Cellebrite DI a Buy, while one rates it a Sell; the average 12-month price target is $14.75. Recent target changes were mixed, with JPMorgan and Lake Street cutting targets while Needham raised its target to $14.
• Quarterly results beat expectations: Cellebrite reported EPS of $0.17 versus a $0.09 consensus and revenue of $149.02 million versus estimates of $145.83 million.
• Near-term revenue guidance raised concern: The company’s $145 million–$150 million Q4 revenue outlook was below analysts’ $151.6 million estimate, while its full-year revenue forecast was broadly in line with consensus.

Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) has earned an average recommendation of "Moderate Buy" from the five research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $14.75.

CLBT has been the subject of a number of research analyst reports. JPMorgan Chase & Co. lowered their price target on Cellebrite DI from $16.00 to $15.00 and set an "overweight" rating for the company in a report on Friday. Weiss Ratings lowered Cellebrite DI from a "sell (d+)" rating to a "sell (d)" rating in a research note on Thursday, August 27th. DA Davidson reaffirmed a "buy" rating and issued a $15.00 price objective on shares of Cellebrite DI in a research note on Tuesday, September 15th. Lake Street Capital decreased their target price on Cellebrite DI from $21.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday, August 14th. Finally, Needham & Company LLC lifted their target price on Cellebrite DI from $12.50 to $14.00 and gave the company a "buy" rating in a research report on Thursday.

Insider Activity at Cellebrite DI

In other news, CMO David Gee sold 4,323 shares of the firm's stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $11.36, for a total value of $49,109.28. Following the sale, the chief marketing officer directly owned 135,281 shares in the company, valued at approximately $1,536,792.16. This trade represents a 3.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO David Barter sold 12,134 shares of Cellebrite DI stock in a transaction that occurred on Friday, October 16th. The shares were sold at an average price of $11.21, for a total transaction of $136,022.14. Following the sale, the chief financial officer directly owned 322,085 shares in the company, valued at $3,610,572.85. This trade represents a 3.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 57,143 shares of company stock valued at $645,005. 5.70% of the stock is currently owned by company insiders.

Institutional Trading of Cellebrite DI

Hedge funds have recently added to or reduced their stakes in the stock. Roubaix Capital LLC boosted its holdings in shares of Cellebrite DI by 108.1% during the 1st quarter. Roubaix Capital LLC now owns 303,215 shares of the company's stock valued at $4,178,000 after acquiring an additional 157,536 shares in the last quarter. Light Street Capital Management LLC increased its holdings in Cellebrite DI by 104.8% in the 2nd quarter. Light Street Capital Management LLC now owns 1,312,755 shares of the company's stock worth $19,166,000 after purchasing an additional 671,830 shares in the last quarter. Lazard Asset Management LLC acquired a new position in Cellebrite DI in the 1st quarter worth about $2,134,000. Nine Ten Capital Management LLC increased its holdings in Cellebrite DI by 19.8% in the 2nd quarter. Nine Ten Capital Management LLC now owns 4,126,808 shares of the company's stock worth $60,251,000 after purchasing an additional 682,933 shares in the last quarter. Finally, Principal Financial Group Inc. raised its position in Cellebrite DI by 33.9% in the first quarter. Principal Financial Group Inc. now owns 2,156,166 shares of the company's stock valued at $29,712,000 after purchasing an additional 545,334 shares during the last quarter. Institutional investors and hedge funds own 45.88% of the company's stock.

Cellebrite DI Trading Up 5.9%

Shares of Cellebrite DI stock opened at $11.53 on Friday. The company has a 50 day moving average of $11.60 and a 200-day moving average of $13.22. Cellebrite DI has a 1-year low of $9.58 and a 1-year high of $19.39. The company has a market cap of $2.88 billion, a PE ratio of 48.04, a price-to-earnings-growth ratio of 1.67 and a beta of 1.06.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.08. The business had revenue of $149.02 million for the quarter, compared to analyst estimates of $145.83 million. Cellebrite DI had a net margin of 12.14% and a return on equity of 17.47%. Research analysts forecast that Cellebrite DI will post 0.37 earnings per share for the current year.

Cellebrite DI News Roundup

These are some of the CLBT news items that stood out recently:

• Positive Sentiment: Needham raised its price target from $12.50 to $14.00 and maintained a Buy rating, signaling confidence in further upside. Needham analyst ratings
• Positive Sentiment: JPMorgan lowered its target from $16 to $15 but kept its Overweight rating, indicating continued optimism despite a more cautious valuation. JPMorgan analyst ratings
• Negative Sentiment: Q4 2026 revenue guidance of $145 million–$150 million fell short of the $151.6 million consensus estimate, raising a near-term concern. Full-year revenue guidance of $553 million–$558 million was broadly in line with the $556.8 million estimate.

About Cellebrite DI

Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company's offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.